From Name:
From Email:
To Name:
To Email:

Optional Message:

Bladder cancer: Model predicts survival after immunotherapy

from Medscape

A prognostic model based on six clinical factors can help predict overall survival in patients with advanced urothelial cancer who are treated with the anti–programmed cell death ligand 1 (PD-L1) immune checkpoint inhibitor atezolizumab (Tecentriq, Roche) after platinum-based therapy. The U.S. Food and Drug Administration has approved five new immunotherapies for advanced UC that has progressed during or after platinum-based chemotherapy, including atezolizumab. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063